Energesis Pharmaceuticals is developing therapeutics for diabetes,聽obesity, and lipid disorders by targeting brown adipose tissue (BAT). The Company鈥檚 approach is a聽novel strategy leveraging recent scientific insights in BAT biology to increase the body鈥檚 ability to聽burn stored fat and lower insulin resistance. Diabetes and its major underlying cause, obesity, have聽reached epidemic proportions in the U.S. and the rest of the industrialized world.聽However, there are presently very few safe and effective non-